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Abstract 
Novel palladium (Pd)-loaded titanium (Ti) devices with high biocompatibility and catalytic activity were 
prepared using a range of fabrication methods such as powder metallurgy (i.e. sintering with and without 
space-holder), sputtering, pulsed laser deposition and supersonic cluster beam deposition. The surface of the 
Ti-[Pd] devices were physico-chemically characterised to confirm the non-alloyed state of the Pd coating 
onto the titanium substrate. The Pd thickness was optimised to achieve maximum surface area (i.e. maximum 
catalytic effect) using the minimum amount of material in each method for cost effective production. The 
catalytic response of the different Ti-[Pd] devices was evaluated under biocompatible conditions by 
employing an off-on Pd-activatable fluorescent probe. The most robust coating of Pd was produced by an 
optimised magnetron sputtering method. The sputtered Ti-[Pd] devices were selected to induce the 
bioorthogonal uncaging of the anticancer drug Vorinostat from a pharmacologically-inactive Pd-activatable 
precursor in cancer cell culture, demonstrating the capacity of these devices to mediate a local anti-tumour 
effect via in-situ release of a clinically approved drug. This approach is the first step towards surgically 
implantable devices that could facilitate targeting affected areas with high spatial selectivity, improving 
pharmacological activity and reducing systemic side effects through localised treatment directly at the cancer 
site. 
Keywords  
Palladium, Titanium, sputtering, deposition, bioorthogonal catalysis, chemotherapy prodrug 
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1. Introduction 
Efforts to eradicate cancer and improve survival rates have led to initiatives from national health systems 
promoting earlier diagnosis, more effective screenings and versatile treatments to improve cancer patient 
prognosis. Despite remarkable advances in overall cancer survival, death rates are increasing for some cancer 
types, including aggressive liver, pancreas, uterus, lung and brain cancers.1-3 In order to extend a positive 
health outcome trend across the entire spectrum of forms of cancer, new therapies and medtech capabilities 
are needed. Novel cancer treatments, for example immunotherapy 4, proton beam radiation 5, photodynamic 
therapy 6 or prodrugs activation therapy 7 aim to support or even replace aggressive approaches such as 
radio- or chemo-therapies, which typically lead to life-threatening secondary effects on patients. Efficacy and 
cost-effectiveness are issues that still remain and there are opportunities to develop further new propositions. 
Bioorthogonal chemistry focuses on the development and application of selective chemical reactions that are 
compatible with biological environments and do not interfere with the normal functioning of its components. 
8, 9 Such reactions are designed to monitor or modulate physiological and pathological processes and can be 
mediated by two or more mutually-reactive chemical groups or in combination with non-biotic transition 
metals (e.g. Cu 10, 11, Au 12, Ru 13, 14 or Pd 15, 16). The use of heterogeneous metal catalysts as bioorthogonal 
tools is currently under investigation for the activation of systemically administered prodrugs at a determined 
location in a catalytic manner (Figure 1).17-20  
 
Figure 1: Strategy for the intratumoural activation of inactive prodrug into cytotoxic drugs via catalyst-loaded carriers 
Such an experimental therapeutic approach aims to introduce a unique local therapy strategy with the 
capacity to elicit long-term release of therapeutics in a spatially-controlled fashion within the landscape of 
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targeted cancer therapies. As a consequence, the development of novel benign transition metal-loaded 
devices has been brought into the spotlight in recent years. 11, 21-23 The manufacture of macro scale structures 
with surfaces containing or coated with such transition metals poses opportunities and challenges. The 
advantages of a device surgically implantable and detectable using current medical imaging technologies (e.g. 
titanium metal) could be forfeited by the challenges of manufacturing a metal-catalytic surface that can 
withstand the stringent physiological conditions inside the body. Metal surfaces and coatings preparation 
methods such as wet chemistry24 (e.g. electrostatic adsorption25 and grafting26), vapour- or gas-phase 
deposition (i.e. chemical27 and physical28), electrochemistry29 (i.e. electroless and electroplating30), plasma or 
thermal spraying 31 have been previously reported. In this study titanium was used as the substrate and it was 
coated using palladium element in its unalloyed state, i.e. Pd0, for catalytic purposes. This transition metal 
was chosen to profit from the wealth of probes and prodrugs that are activated by Pd chemistry.17-20, 32, 33A 
suitable manufacturing process for the devices had to comply with the following requirements: realisation of 
highly conformal nano-scale surfaces; achieved at low substrate temperatures to prevent metal alloying or 
surface oxidation34; avoid the use of toxic precursors or intermediates that could contaminate the exposed 
surface35 and be both cost and time effective. Powder metallurgy and physical deposition methods were 
therefore selected on account of their compliance with these processing requirements.  
The devices’ catalytic efficiency was tested through the uncaging of a prodye (a non-fluorescent compound) 
to obtain fluorescent Rhodamine 110 dye upon Pd-mediated O-depropargylation. The Ti-[Pd] devices were 
optimised by tailoring their physical features (i.e. shape, dimensions and specific surface area) and chemical 
composition. Subsequently to investigate their capability as chemotherapeutic drug activator, a bioorthogonal 
Pd-labile prodrug of the histone deacetylase inhibitor Vorinostat (SAHA), an anticancer drug 20, was 
incubated with the devices in cancerous cell culture in order to assess its conversion into the active 
antitumour drug.  
2. Materials and Methods 
2.1. Materials 
Ti powder (Alfa Aesar, USA, -325 mesh, average particle size ≤44 µm, 99.5% purity) and Pd powder 
(Aldrich Co., UK, -200 mesh, average particle size ≤74 µm, 99.9% purity) were used for the fabrication of 
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the sintered carriers. NaCl particles (Sigma Aldrich, UK, +80 mesh, average particle size 177 µm, ≥98% 
purity) were used as space holders to mix with the Pd powder. Prior to that, the NaCl particles were sieved 
(AS 400 control, Retsch, Germany) and separated into the following size range groups: (i) 45-106 µm; (ii) 
106-212 µm; (iii) >212 µm. A final group (iv) of random particles (45-212+ µm) was also used. A Pd disc 
(PI-Kem Ltd, UK, 57 mm diam, 0.1 mm thickness, 99.99%) was used as target for the sputtering process. A 
Pd target (Testbourne Ltd, UK, 15x15x2 mm, 99.99%) was used for the pulsed laser deposition process. A 
Pd rod (Goodfellow, ITA, 6 mm diam, 10 mm length, 99.95%) was used for the supersonic cluster beam 
deposition method. For the probe/prodrug activation assays, chemicals and solvents such as Rhodamine 110 
chloride, N,N-dimethylformamide (DMF), Propargyl chloroformate and N,N-Diethylethanamine (i.e. 
trimethylamine) were purchased from Fisher Scientific UK, Sigma-Aldrich or VWR International Ltd. 
Vorinostat (SAHA) was purchased from Cayman Chemical Co. UK. All chemicals and solvents were >95% 
pure according to the supplier’s information. Synthesized compounds were >95% pure as measured either by 
HPLC and/or NMR and TLC. NMR spectra were recorded at ambient temperature on a 500 MHz Bruker 
Avance III spectrometer. Analytical TLC was performed using Merck TLC Silica gel 60 F254 plates and 
visualized by UV light. Purifications were carried out by flash column chromatography using commercially 
available silica gel (220-440 mesh, Sigma-Aldrich). Fluorescence signal in the fluorogenic assay and in the 
reusability study was obtained in a PerkinElmer Victor multilabel spectrophotometer (excitation filter at 480 
nm and emissions filter at 535 nm) and is reported in Relative Fluorescence Units (RFU). Fluorescence 
emission for the cytotoxicity studies was measured using a PerkinElmer Victor multilabel reader (excitation 
filter at 540 nm and emissions filter at 590 nm). Stock solutions (100 mM) were prepared in biological grade 
DMSO. 
2.2. Sintering method (S) 
Pd wafers were prepared using Pd powder only, cold pressed in a 10mm diameter stainless steel die to 20 kN 
applying a vertical load (Press 40 Specac, Atlas, UK). The Pd wafers were sintered in a vacuum furnace 
(LTF 1400C, Lenton, USA equipped with a HiCube 80 pump, Pfeiffer, Germany) at 1,000 °C for 1 h and10-5 
mbar to prevent any oxidation. After natural cooling to room temperature, the wafers were polished 
(EcoMet250, Buehler, USA) manually using 320 and 1200 grit SiC paper until a shiny finish was achieved. 
Samples were prepared in triplicate and used without further treatment. 
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2.3. Sintering and space holder method (Sx) 
Ti powder (0.35 g) was poured into a 10mm diameter mould. Meantime, the Pd powder (0.21 g) was mixed 
with the space holder (NaCl, 0.09 g) in the four size ranges (Si, Sii, Siii, Siv) in a ratio 2.21 Pd:NaCl to 
obtain a 70% volumetric nominal porosity.  The mixture was poured into the 10 mm diam mould  where the 
Ti powder awaited and then conjointly subjected to cold isostatic pressing (as above, at 25 kN) followed by 
sintering at 1,000 °C for 1 h in a vacuum furnace (as above) to avoid oxidation of the samples. After natural 
cooling to room temperature the specimens were profusely washed in distilled water to remove the space 
holder.  Samples were prepared in triplicate in the 4 size ranges of the space holder. The samples were used 
without further treatment. 
2.4. Sputtering method (SP) 
A 2 mm height Ti disc was prepared through the same cold isostatic process (as above) using a die of 16 mm 
diameter and compressing to 250 MPa. This Ti disc was sintered in the vacuum furnace at 1,200 °C for 2 h 
and <10-5 mbar as above. Once the samples had cooled naturally to room temperature these were ground and 
polished (EcoMet250 and AutoMet250, Buehler, USA) using the following routine applying 15 N of 
downward force: 320, 600 and 1200 grit SiC paper at 180 rpm and water cooled until flat surface, then 9 µm 
diamond suspension on a counter-rotating ultra-pad cloth at 120 rpm for 10 min. The final polishing step 
involved the use of 1 µm colloidal silica using a microcloth pad using the same rotation settings. The 
sintered and polished Ti discs were sputtered in a Magnetron sputtering system (Q150T ES, Quorum 
Technologies Ltd, UK) using a pure Pd disc target in the vacuum chamber at 10-5 mbar after Ar flushing with 
a current of 40 mA and sputtering at a pressure of 9x10-3 mbar . The deposition rate for the coating was set to 
21 nm/min to achieve a coating thickness set to 42 nm and to 62.8 nm. Samples were prepared in 
quadruplicate and used without further treatment.   
2.5. Pulsed laser deposition method (PLD) 
Ti discs manufactured using the same procedure as above (see ‘Sputtering method’ section) were mounted 
onto a bespoke stainless steel holder and placed in the laser chamber, designed to perform deposition on 
large areas. More details on the process have been reported. 36 The chamber was heated to 120 °C, vacuum 
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flushed and left to cool down naturally to room temperature (24-48 h), which created a base pressure of 10-9 
mbar. The Pd target was placed 10 cm distant from the sample, and the laser (840 mW, GCR-5 solid state Q-
switched Nd:YAG, Polaron C V T Ltd., UK & IFW Dresden, GE) emitted 10 pulses/s with visible light at 
532 nm wavelength. The coating on each sample was aimed to be 65 nm and it took 2.5 h to complete. The 
samples were prepared in duplicate and used without further treatment. 
2.6. Supersonic cluster beam deposition method (SCBD) 
Ti discs manufactured using the same procedure as above (see ‘Sputtering method’ section) were treated 
with this method, devised for microstructured metallisation of surfaces, at Prof M Milani’s lab (University of 
Milano, Italy) following the process previously described. 37 Using a Pd rod as target, Pd clusters were 
formed in the gas phase using a pulsed microplasma source, expanded through a nozzle to generate a 
supersonic gas stream and deposited at a typical rate of 0.5 nm/min on the Ti discs in vacuum at10-7 mbar 
with an aimed mean film thickness of 42 nm (as measured by the quartz microbalance). The samples were 
tested without any further treatment. 
2.7. Screening of devices’ surface chemical properties   
Synthesis of bis-N,N’-propargyloxycarbonyl-rhodamine 110 (prodye). The prodye was synthesised 
according to literature procedure.17 Briefly, rhodamine 110 chloride was dissolved in dry DMF under 
nitrogen atmosphere. Separately, propargyl chloroformate and triethylamine were added dropwise to the 
mixture. The reaction mixture was stirred at room temperature for 48 h and then purified by chromatographic 
column. The spectral data matched the values reported in the literature.17 Purity was >95% measured by TLC 
and NMR 
Fluorogenic assay (prodye-to-dye conversion). The prodye, which presents its fluorescence properties 
quenched, was used to determine the catalytic efficiency of the Ti-[Pd] devices previously manufactured. 
They were set in 22x40 mm glass vials. A solution of prodye (100 μM) in PBS (pH = 7.4) was prepared and 
2 mL were added to each vial containing Ti-[Pd] devices. The mixtures were stirred at 250 rpm using a 
magnetic-stirring-bar at 37 °C in an oil bath. The release of Rhodamine 110 was measured after 24 h by 
fluorescence at λex/em= 480/535 nm.  
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Reusability study. Ti-[Pd] devices were taken carefully with flat tweezers and were washed in 5 mL 
distilled water. The manufactured devices were set in a new 22x40 mm glass vials. A 2 mL fresh solution of 
prodye at 100 μM in PBS (pH = 7.4) was added to each vial containing the device. The mixtures were stirred 
at 250 rpm using a magnetic-stirring-bar at 37 °C in an oil bath. The release of Rhodamine 110 (mechanism 
described in Figure 5) was detected after 24 h of treatment by fluorescence. This cycle was repeated 5 times. 
Synthesis of O-(4-Propagyloxybenzyl) suberoylanilidehydroxamate (prodrug POB-SAHA).  O-(4-
Propagyloxybenzyl) suberoylanilide hydroxamate (namely POB-SAHA thereafter) was synthesised by 
treatment of SAHA with 4-(propargyloxy)benzyl bromide and 1,8-diazabicyclo[5.4.0]undec-7-ene at room 
temperature for 24 h according to literature procedure.20 1H-NMR, 13C-NMR and HPLC analyses matched 
with literature.20 
2.8. Biological ‘in vitro’ studies of the surfaces: cytotoxicity and prodrug activation 
Cell culture. Human lung adenocarcinoma A549 cells (kindly donated by Dr Simon Wilkinson, University 
of Edinburgh, UK) were cultured in Dulbecco’s Modified Eagle Media (DMEM) supplemented with serum 
(10% FBS) and L-glutamine (2 mM) and incubated in a tissue culture incubator at 37 °C and 5%  CO2.  
Preparation of Ti-[Pd] devices for biological testing. A set of 6 discs of 3 mm of diameter and 2 mm in 
height manufactured using the SP method were sterilized in an autoclave at 121 °C for 20 min and under UV 
light for 10 min before treatment. 
Cytotoxicity study: The cytotoxicity of the SP Ti-[Pd] devices to the cells was assessed using a 
PrestoBlue™ cell viability assay against A549 cells. The Prestoblue™ viability assay contains a cell 
permeable resazurin-based solution that functions as a cell viability indicator by using the reducing power of 
living cells to quantitatively measure their proliferation. SP Ti-[Pd] devices were cultured in a 24-well plate 
with 20,000 cells/well for 72 h. Untreated cells were used as control. At that time point Prestoblue™ reagent 
was added into each well according to the manufacturer’s protocol. The plate then was incubated at 37 °C in 
humidified atmosphere for 120 min. Fluorescence emission was detected at  λex/em= 540/590 nm. The test 
was performed in triplicate.  
Activation of prodrug (POB-SAHA) catalysed by SP Ti-[Pd] devices in cancer cell culture and 
tolerability study. A549 cells were seeded in a 24-well plate format (at 20,000 cells/well) and incubated for 
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24 h before Pd-mediated activation tests. Media was then aspirated and the SP Ti-[Pd] devices carefully 
placed onto the surface of each well. Cells were treated with prodrug POB-SAHA (100 μM) or SAHA (100 
μM) accordingly and incubated for 72 h. This concentration was selected according to previous reported 
results.20 Cells treated with only DMSO (0.1% v/v) were used as control. All experiments were performed in 
triplicate. PrestoBlueTM cell viability reagent (10% v/v) was added to each well and the plates were incubated 
for 120 min. Fluorescence emission was measured as explained in the previous section.  All conditions were 
normalized to the untreated cells (100%) and data analysed using GraphPad Prism. 
2.9. Characterisation 
The surface area of the Pd-carrying devices was measured using a metrology protocols (3D micro coordinate 
InfiniteFocus, Alicona, Austria) with x5 magnification and using a polarised light with vertical and 
horizontal resolution of 3.22 µm and 7.82 µm, respectively. A field emission scanning electron microscope 
SEM/EDS (TM3030/JSM-7800F, Hitachi, Japan) was employed to inspect the surface and to determine the 
elemental composition of the samples, including the detection of any contamination on the surfaces. X-ray 
diffraction (benchtop 2phase diffractometer r, Bruker, Germany) tests were conducted at room temperature 
using a Cu K-alpha source, 30 kV, 20 mA radiation and 0.020 °/step to assess the crystal structure of the Pd 
deposited and to identify any episode of alloying. X-ray Photoelectron Spectroscopy (K-Alpha XPS, Thermo 
Scientific, UK) using monochromatic Al Kα radiation micro-focussed to a spot size of 200 µm in 5 μm steps 
was used to identify the electronic state of the elemental composition and also any Pd oxide contaminant 
present using a constant analyser energy mode (CAE) at 200 eV pass energy for elemental spectra. Elemental 
quantification was done with standard single element sensitivity factors using the Thermo Advantage 
software (TA Instruments, UK). The main photoelectron peaks considered were Pd 3d, C 1s, O 1s, Na1s, Ti 
2p and N 1s. XPS was also employed to assess layer thickness using an Al anode (beam diameter 400 μm, 
power 36 W). XPS depth profiling was done using a 0.5keV argon ion beam, over an area of 2×2 mm and a 
drilling rate of 0.0878 nm/min, calibrated on a Ta2O5 substrate. X-ray fluorescence (Orbis PC Micro-XRF 
Analyzer, EDAX, USA) equipped with an Rh tube for 50 kV and 50 W was used to assess coating thickness 
using 5 places on the sample systematically (i.e. centre, top, bottom, left and right), and Atomic Force 
Microscopy (AFM, Veeco Explorer, USA) was used to confirm such measurements using a Si cantilever 
(AFM probe-Bruker TESP-MT) applying a force of 20-80 N/m at 330 kHz of resonance frequency. The 
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scans were conducted at three randomly identified locations and the images analysed using the XEI 1.8 
software (Park Systems, South Korea). A Focused Ion Beam (FIB-SEM) system (Nova200 NanoLab, FEI, 
US) was used to obtain thin slices of the samples in order to measure the thickness of the Pd coating using 
SEM images.  
3. Results 
Substrates of titanium coated with metallic palladium (Pd0) or palladium-only discs were manufactured using 
powder metallurgy and physical deposition methods to create implantable devices that possess a conformal, 
stable surface for high-yield catalytic reactions. The devices were physico-chemically characterised. Having 
confirmed the devices displayed sufficient structural integrity and were of an adequate size for handling, the 
main feature of interest was the existence and quantity of Pd0 species on its surface. Crystallographic (i.e. 
XRD) results from S samples presented a single Pd cubic state element with no other accompanying peak. 
The manufactured samples (Sx, SP, PLD and SCBD) (Figure 2) showed the presence of both Ti and Pd 
species in their cubic state. The Sx series presented, in addition, TixOx compounds.   
 
Figure 2: XRD comparison for the Ti-[Pd] devices manufactured using the different methods (♦: Pd; ●: Ti; ○: TiO2) 
Results from XPS tests (Figure 3) showed 2 dominating peaks at 335.33 ± 0.06 eV (Pd3d5/2) and 340.85 ± 
0.26 eV(Pd3d3/2), confirming the presence of Pd in its metallic form and with no PdO formed (which would 
appear with shifted peaks at 337.3 eV (Pd3d5/2) and 342.5 eV (Pd3d3/2) respectively). An additional peak at  
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530.3 eV, which corresponds to the O1s peak resolved for the oxygen present on PdO 38, 39 would have 
appeared, but the present study shows  peaks at 527 and 562 eV instead (those corresponding to that of the 
background signal, not to the formation of PdO). A C layer, whose (C1s) peak appeared at binding energy 
284 eV, which corresponds to the sp2 carbon peak, was present but its intensity decreased after 2 cycles of 
Ar etching, confirming it was only superficial contamination. Further enquiries over an Ag peak at 366 eV 
(Ag3d), which corresponded to AgBr, and a Br peak at 68.9 eV, corresponding to Br but also overlapping 
Na2s, appeared to belong to the background signal. Sintered Pd wafers (S) (Figure 3, insert) presented a 
dominating peak of C1s with respect to the Pd3d peak expected.  
 
 
Figure 3: XPS survey spectra for the Ti-[Pd] devices surface manufactured using the different methods under study 
(inset: 190-590eV range for S samples) 
The surface area values obtained are reported in Table 1, along with the mass of Pd deposited on each of the 
samples manufactured using the different methods in this study. The primary thickness measurement 
procedure was XRF, and these measurements were confirmed with results from AFM and/or FIB-SEM 
techniques (Figure 4). The mass of the Pd for the sintered (S) and sintered with space holder (Sx) devices 
was the amount of Pd powder used in their manufacture, and for the magnetron sputtered (SP), pulsed laser 
deposition (PLD) and supersonic cluster beam deposition (SCBD) methods this mass was calculated from 
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the surface area, the thickness of the Pd coating and the Pd density (12.02 kg/m3, as per manufacturer’s data). 
The ratio (mm2/g) gives an indication of the spread of the Pd on the surface on each scaffold.   
 
Figure 4: SEM micrograph of the FIB slice displaying the Pd coating sandwiched between the Ti substrate and the 
support film (Pt) for the cutting operation, and the measurement thereafter (inset) 
Table 1: Measured surface area and mass of Pd for the Ti-[Pd] devices manufactured using the methods under study  
Manufacturing 
method 
Sample 
Surface Area 
(mm2) (SD) 
Thickness of Pd 
coating (nm) 
Mass of Pd 
(SD) 
Ratio 
A(mm2):W(g) 
(SD) 
Sintering (S) Pd wafer 
142.013 
(6.039)† 
n/a 
0.162 g 
(0.014) 
876.624 (80.459) 
Sintering with space holder on Pd layer (Sx)   
Si 
Size range: 
45-106 µm  
147.577 
(6.842) 
n/a 
0.210 g 
(0.005) 
702.748 (36.626) 
Sii 106-212 µm 
144.835 
(26.095) 
n/a 
0.209 g 
(0.007) 
692.990 (126.995) 
Siii >212 µm 
135.560 
(11.960) 
n/a 
0.206 g 
(0.001) 
658.058 (120.594) 
Siv random 
114.095 
(12.445) 
n/a 
0.209 g 
(0.000) 
545.909 (59.545) 
Sputtering (SP) 
Sintered Ti 
base/Pd 
coating 
172.322 
(6.251) 
67.600 (3.226) 
[65.028]AFM 
[66.706]FIB/SEM 
0.138 mg 
(0.005) 
1248.710 e3 
(62.658 e3) 
Pulsed Laser 
Deposition 
(PLD) 
Sintered Ti 
base/Pd 
coating 
187.43 
(12.093) 
69.085 (1.515) 
[66.30]AFM 
0.153 mg 
(0.001) 
1225.033 e3 
(112.579 e3) 
Supersonic 
cluster beam 
deposition 
(SCBD) 
Sintered Ti 
base/Pd 
coating 
212.550 
(7.640) 
50.76 (14.75) 
[50.5]AFM 
0.130 mg 
(0.038) 
1635.000 e3 
(481.523 e3) 
†Total surface area, including both sides 
[..]AFM or FIB/SEM, thickness confirmed using these methods 
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The catalytic efficiency of the Ti-[Pd] devices to convert the non-fluorescent prodye into green fluorescent 
Rhodamine 110 was determined by spectrofluorometry (Figure 5). Fluorescence intensity (RFU) values 
obtained from each of the devices are reported in Figure 5a. To obtain a better picture of the efficacy of each 
of the devices, RFU values were also normalised with respect to the mass of Pd present on the surface of 
each device surface as well as the ratio surface area to mass of Pd (Figure 5b). 
 
Figure 5: Fluorogenic assay used to determine the catalytic properties of the Ti-[Pd] devices surface. Catalytic 
efficiency reported as: a) Fluorescence signal obtained for Ti-[Pd] devices after incubation for 24h with the non-
fluorescence probe in physiological conditions; b) normalised RFU/g values compared against Surface Area/Pd mass 
ratio of each device 
The results from the reusability study (i.e. 5 cycles of the fluorogenic assay) are shown in Figure 6 and are 
reported in the normalised format with regards to the amount of Pd mass on the device. This test permitted 
the assessment of each manufacturing method attending to the Ti-[Pd] devices’ catalytic potency when 
subjected to sequential catalytic reactions. 
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Figure 6: Reusability study of catalytic deprotection of the surface to 5 cycles presented left to right using the Prodye in 
PBS for 24h on each Ti-[Pd] device manufactured via the different methods 
Figure 7 shows SEM analysis on the samples before and after the fluorogenic tests. The images obtained 
after the tests on the SP, PLD and SCBD samples present evident effects of chipping and pitting, suggesting 
degradation and detachment of the Pd coating over the cycles. This effect was evaluated through a study on 
the elemental composition of the Pd film using XPS data on the prevalence of the Pd3d metal species (Table 
2), which informed on the amount of Pd0 available for the fluorogenic assay on the pristine samples (Table 2, 
‘before’ row), as well as through reusability tests using the prodye-into-dye conversion (Table 2,‘after’).  
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Table 2: Elemental study on the samples, reported as atomic %, of the main species (incl. Pd3d metal availability for the biochemical tests and C1s, O1s content on the 
surface along with other minor species) as pristine samples (‘before’) and as-used samples (‘after’) 
Sample 
series Before biochemical tests (atomic %) (SD) After biochemical tests (atomic %) (SD) 
 Pd3d C1s O1s Na1s Ti2p N1s Pd3d C1s O1s Na1s Ti2p N1s Si2p 
S 
75.325 
(0.095) 
26.156 
(13.977) 
20.552 
(13.596) 
- - 6.659 
(2.508) 
2.535 
(0.655) 
60.25 
(7.870) 
20.900 
(9.095) 
- - 3.671 
(1.879) 
16.971 
(4.367) 
Sx 
36.105 
(9.525) 
33.943 
(5.866) 
18.931 
(14.348) 
3.370 
(2.970) 
5.790 
(3.470) 
7.010 
(1.876) 
6.120 
(9.428) 
44.907 
(9.857) 
28.995 
(8.843) 
4.151 
(2.740) 
8.845 
(3.390) 
- - 
SP 
76.045 
(2.535) 
23.362 
(8.019) 
14.462 
(10.464) 
- - 7.630 
(1.081) 
15.865 
(1.345) 
65.82 
(18.334) 
16.630 
(11.332) 
- - 5.500 
(2.340) 
3.492 
(2.577) 
PLD 
44.435 
(4.865) 
37.133 
(5.269) 
12.163 
(6.548) 
1.411 
(0.876) 
- - 10.540 
(1.310) 
62.021 
(10.333) 
30.324 
(10.002) 
- - 2.833 
(1.909) 
- 
SCBD 
55.770 
(25.260) 
35.837 
(7.498) 
14.591 
(12.750) 
4.079 
(2.055) 
- 8.831 
(3.045) 
4.825 
(3.925) 
36.83 
(12.977) 
34.595 
(13.474) 
3.836 
(2.899) 
23.105 
(16.775) 
- - 
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Figure 7: SEM surface images of Ti-[Pd] devices manufactured using the different methods reported before (top row) and after (bottom row) the prodye-to-dye catalytic 
deprotection tests (scale bar 20 µm) 
 
Page 15 of 24 New Journal of Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
N
ew
Jo
ur
na
lo
fC
he
m
is
tr
y
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
11
 D
ec
em
be
r 2
01
8.
 D
ow
nl
oa
de
d 
by
 L
ou
gh
bo
ro
ug
h 
U
ni
ve
rs
ity
 o
n 
12
/1
1/
20
18
 9
:4
0:
13
 A
M
. 
View Article Online
DOI: 10.1039/C8NJ05704D
16 
 
Given the superior catalytic properties of the SP Ti-[Pd] discs these were selected for the biological studies. 
Cell cytotoxicity was studied by direct incubation of lung carcinoma A549 cells with the SP Ti-[Pd] discs for 
3 days and compared to untreated control cells. Cell viability was quantified via the Prestoblue™ assay. The 
results shown in Figure 8 demonstrate no cytotoxicity induced by the SP Ti-[Pd] devices. Treatment of the 
A549 cells with the prodrug POB-SAHA (inactive) in the absence of the devices did not show cytotoxic 
activity and yielded a cell viability rate close to those of the control. In contrast, the A549 cells incubated 
with the prodrug POB-SAHA in the presence of the SP Ti-[Pd] discs displayed poor levels of tolerability. 
Cell viability dropped to the same levels obtained by direct treatment with the active drug SAHA, 
demonstrating the in-situ uncaging of POB-SAHA by the Ti-[Pd] devices.  
                  
Figure 8: Cell viability and tolerability studies using the Ti-[Pd] device surface to activate prodrug (POB-SAHA) to 
active antitumour drug (SAHA) in the presence of the Ti-[Pd] device (SP discs+ POB-SAHA, hatched green), 
compared to untreated cells control (black), cells treated only with SP Ti-[Pd] device (SP discs, green), cells treated 
only with POB-SAHA (negative control, blue), and cells treated with SAHA (positive control, orange) 
4. Discussion 
The use of implantable devices with a catalytically active surface to enable focused and localised anticancer 
therapies is not a new concept.40-43 One of such technologies are carmustine-containing GliadelTM wafers, 
which are used clinically for postsurgical treatment of brain tumours.44 These devices are however limited by 
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their cargo capacity, being rendered useless once the drug content has been released. Catalyst-loaded devices 
have been recently proposed as an alternative to resolve this issue. Transition metals such as Pd are optimal 
to mediate continuous catalytic manufacture of bioactive small molecules in living systems and, 
consequently, different kinds of Pd-functionalized materials have been investigated in recent years.15, 20, 45 
The novelty presented in this work lies in the strategy deployed by the chosen device, a functionalised Ti 
scaffold whose surface possesses bioorthogonally catalytic capabilities through the incorporation of Pd on 
the top layer of the device. Shape-ability is an important feature to aid implantation procedures since the size 
and location of the targeted tissue may present anatomical challenges. While a range of techniques deriving 
from evaporation methods (e.g. plasma-assisted atomic layer deposition46) have been developed to counteract 
the limitations posed when depositing high surface energy products, such as Pd, onto non-wettable substrates, 
such as Ti47, only those based on the physical deposition of the coating were pertinent to this study. 
Furthermore, the manufacturing processes considered in this work allowed for freedom in the device’s 
construct utilising the minimum amount of raw Pd required, thus lowering the device’s production cost, and 
maximising its surface area and availability of metallic Pd (Pd0) for an effective catalytic reactivity when in 
contact with the Pd-sensitive molecules.  Several methods for the design and manufacture of these catalyst-
loaded carriers were studied, using Titanium as the carrier due to its biocompatibility and contrast-agent 
properties 48, which could facilitate tracking during the implantation of the device and monitoring throughout 
the treatment. Loading of the catalyst onto the carrier was addressed to increase the device’s catalytic 
bioactivation activity. Manufacturing methods tested included powder metallurgy (i.e. sintering with and 
without space holder to increase roughness and therefore increase surface area) and other coating deposition 
methods explored to develop highly conformal thin coatings and active surfaces: magnetron sputtering, 
pulsed laser deposition and supersonic cluster beam deposition. A strict control on the specific surface area, 
minimising the weight to volume ratio, and a high purity of the catalyst, helped to enhance the catalytic 
activity the Ti-[Pd] devices. A study of the thickness of Pd0 coated on the titanium substrate demonstrated 
that methods such as magnetron sputtering, pulsed laser and supersonic cluster beam deposition achieved the 
thinnest of the coating Pd0 layers, making these the most cost effective way of creating catalytic-active 
devices.    
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The results from XRD studies (Figure 2) show that alloying between the Ti and Pd did not occur in any of 
the manufactured devices and the Pd element was retained in its cubic form. The passivating layer of 
titanium oxide formed on the Ti surface helped avoiding the alloying with the Pd.  The Sx series presented 
TiO2, whose formation was promoted by the presence of NaCl in the sintering stage through a chloride route. 
49 The existence of Na1s peaks in the XPS analysis are remains from the space holder that contaminated the 
exposed surface. For this reason, along with their poor performance with regards to the surface area:Pd mass 
ratio and the decreased reusability potency beyond the 3rd cycle, the Sx series specimens were discarded as 
devices suitable for the application.   
Studies on the surface using XPS results further assisted in the assessment of the S samples (Figure 3, inset 
and Table 2). Large standard deviation (SD) in the XPS spectra values of pristine samples indicate the 
susceptibility of the surface to attract O1s and C1s species of organic nature (i.e. pollution) after Ar etching 
the surface. Their large mass and the presence of a substantial C layer (C1s peak) made them less reactive to 
the catalytic deprotection. These are the only substrate-less samples (without Ti) and although this can be 
initially seen as an advantage from a lean manufacturing viewpoint, their production cost is the highest of all 
the series, which renders them less attractive for the application. They also performed poorly in the 
reusability tests, failing to retain any catalytic potency beyond the 2nd cycle, and the Si2p peak present after 
the tests is attributed to other contaminants on the surface. 
According to the position of the Pd3d peak and its intensity on the XPS spectra performed on the SP, PLD 
and SCBD Ti-[Pd] devices, the chemical state of metallic Pd was confirmed in these devices. SP were the 
devices that exhibited the highest of Pd3d peak intensity and SCBD the ones with the least retention 
presenting a significant amount of Ti2p post tests, depleted of Pd0 coating.  The quantification of the O1s 
peaks has been reported in Table 2 and these peaks correspond to the organic (i.e. background) C-O and 
C=O compounds which proved difficult to eliminate despite plasma etching during the XPS analysis. The 
presence of Na1s peaks can be tracked down to the manufacturing route of the raw Ti powder which is the 
main constituent of the substrate.49  
The results from the fluorogenic studies correlated well with the on-surface tests performed on the Ti-[Pd] 
devices. Despite the SCBD devices generating the highest fluorescence signal when compared to SP and 
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PLD devices, the surface SEM images obtained after the test presented clear signs of chipping and 
detachment of the coating (Figure 7, last column). This was confirmed with the results from the reusability 
tests, with a marked reduction in catalytic activity after the 1st cycle, and by the surface exploration after the 
tests (Table 2). Concurrently, it can be observed that the Ti-[Pd] devices manufactured using the PLD 
method show a plateaued fluorogenic signal after the 1st cycle and compared to the successive ones (Figure 
6). These results show depletion in catalytic-deprotection activity after the 2nd cycle and are symptomatic of 
poor integrity of the substrate and its coating.  
The SP Ti-[Pd] devices surface reported a higher fluorogenic signal, sustained over the reusability tests, and 
given the smaller quantities of Pd used, their production is therefore more cost-effective. Consequently, it 
was concluded that the magnetron sputtering method (SP) was the best manufacturing route to functionalise 
the devices in a facile, reliable and faster manner. This method allowed the preparation of catalyst-loaded 
devices with good reusability results, probably due to good adhesion strength at the Pd|Ti interface and 
highly conformal coating. This result is in agreement with previous work.50 Therefore, these SP Ti-[Pd] 
devices were selected for the cell-based studies.  
Their potential application to modulate the spatiotemporal generation of a chemotherapeutic drug from an 
inactive precursor was assessed in cell culture conditions. A 3-day cytotoxicity study confirmed full 
biocompatibility of the SP Ti-[Pd] devices in human lung carcinoma cell culture. The prodrug POB-SAHA, a 
completely inactive derivate of the histone deacetylase inhibitor SAHA that is susceptible to deprotection in 
the presence of Pd0, was combined in a A549 cell culture with the Ti-[Pd] devices. This combination elicited 
a potent cytotoxic effect, unequivocal evidence that the active drug is rapidly released in standard cell culture 
conditions. As previously reported, the mechanism of POB-SAHA deprotection catalyzed by Pd proceeds via 
O-depropargylation of a phenolic ether group followed by spontaneous 1,6-elimination of the p-
hydroxybenzyl intermediate.20 Treatment of A549 cells with POB-SAHA (negative control) manifested no 
effect on the cells, while cells treated with SAHA (positive control) induced widespread cell mortality 
(Figure 8).51 
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5. Conclusions 
Due to the lack of selectivity and unwanted side effects of current chemotherapies, the design of drug-eluting 
devices that can be implanted inside tumours to release cytotoxic agents only at the disease site is an 
important area of research. Local therapy technologies (e.g. drug-eluting implants) can reduce systemic side 
effects of chemotherapy treatments but are restricted by a limited loading capacity. Once the drug content is 
released in full, the devices become obsolete. To solve this limitation, we have developed a novel Pd-coated 
Ti carriers with catalytic surfaces as implantable “activating” devices which are innocuous but capable of 
mediating the spatiotemporal generation of chemotherapeutic drugs from an inactive precursor in cell culture 
conditions. With stringent design specifications determining the manufacture of the device, several 
fabrication processes were investigated and the surface performance of the products assessed with regards to 
their structural integrity, production costs and efficacy on a fluorogenic assay that informed of the 
bioorthogonal uncaging potency of the Ti-[Pd] devices. Cell based studies with the best-performing type of 
devices (i.e. magnetron sputtered) demonstrated the full biocompatibility and capacity to synthesise in-situ a 
clinically used drug in lung cancer treatment (i.e. SAHA). This capacity is tightly correlated to the 
functionalised surface of the device and the availability of Pd in its metallic form (Pd0).  The results from this 
study confirmed the selection of a protocol that fulfils the design requirements, could aid mass customisation 
of catalyst-loaded carriers and permits a cost-effective production of these devices that could take us a step 
closer towards achieving continuous intratumoural release of anticancer drugs in the clinic. 
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